Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELP Study Extension: Lanadelumab in HAE
NCT02741596Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2016
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, open-label trial of lanadelumab in hereditary angioedema (HAE) (2 arms), sponsored by Takeda. Primary endpoint: Number of Participants With Treatment-emergent Adverse Events at Day 952. Started May 2016; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT02741596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02741596.